JPWO2019209692A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019209692A5 JPWO2019209692A5 JP2020558958A JP2020558958A JPWO2019209692A5 JP WO2019209692 A5 JPWO2019209692 A5 JP WO2019209692A5 JP 2020558958 A JP2020558958 A JP 2020558958A JP 2020558958 A JP2020558958 A JP 2020558958A JP WO2019209692 A5 JPWO2019209692 A5 JP WO2019209692A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- optionally substituted
- azaspiro
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 126
- 150000001875 compounds Chemical class 0.000 description 60
- -1 azetidyl Chemical group 0.000 description 54
- 125000000217 alkyl group Chemical group 0.000 description 29
- 125000001424 substituent group Chemical group 0.000 description 18
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 17
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 17
- 125000001072 heteroaryl group Chemical group 0.000 description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000005936 piperidyl group Chemical group 0.000 description 5
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 4
- 229960002707 bendamustine Drugs 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 4
- 229960004942 lenalidomide Drugs 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 1
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024041949A JP2024073590A (ja) | 2018-04-23 | 2024-03-18 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661525P | 2018-04-23 | 2018-04-23 | |
| US62/661,525 | 2018-04-23 | ||
| PCT/US2019/028471 WO2019209692A1 (en) | 2018-04-23 | 2019-04-22 | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024041949A Division JP2024073590A (ja) | 2018-04-23 | 2024-03-18 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523885A JP2021523885A (ja) | 2021-09-09 |
| JPWO2019209692A5 true JPWO2019209692A5 (es) | 2022-05-02 |
| JP7458324B2 JP7458324B2 (ja) | 2024-03-29 |
Family
ID=66641467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558958A Active JP7458324B2 (ja) | 2018-04-23 | 2019-04-22 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
| JP2024041949A Pending JP2024073590A (ja) | 2018-04-23 | 2024-03-18 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024041949A Pending JP2024073590A (ja) | 2018-04-23 | 2024-03-18 | 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11358952B2 (es) |
| EP (2) | EP3784663B1 (es) |
| JP (2) | JP7458324B2 (es) |
| KR (1) | KR20210003103A (es) |
| CN (2) | CN113214220B (es) |
| AR (1) | AR114803A1 (es) |
| AU (2) | AU2019261273B2 (es) |
| BR (1) | BR112020021552B1 (es) |
| CA (1) | CA3096404A1 (es) |
| CL (1) | CL2020002696A1 (es) |
| CO (1) | CO2020012824A2 (es) |
| DK (1) | DK3784663T3 (es) |
| EA (1) | EA202092248A1 (es) |
| ES (1) | ES2959622T3 (es) |
| FI (1) | FI3784663T3 (es) |
| HR (1) | HRP20231199T1 (es) |
| HU (1) | HUE064340T2 (es) |
| IL (1) | IL277435B1 (es) |
| LT (1) | LT3784663T (es) |
| MX (2) | MX2020011183A (es) |
| PE (1) | PE20211375A1 (es) |
| PL (1) | PL3784663T3 (es) |
| PT (1) | PT3784663T (es) |
| RS (1) | RS64663B1 (es) |
| SG (1) | SG11202009237XA (es) |
| SI (1) | SI3784663T1 (es) |
| TW (1) | TWI814815B (es) |
| WO (1) | WO2019209692A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| AU2020372334A1 (en) * | 2019-10-21 | 2022-05-05 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
| MX2022004688A (es) * | 2019-10-21 | 2022-05-10 | Celgene Corp | Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona. |
| CA3154510A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| EP4048233A1 (en) | 2019-10-21 | 2022-08-31 | Celgene Corporation | Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same |
| CN115087448A (zh) * | 2019-10-21 | 2022-09-20 | 新基公司 | 使用2-(2,6-二氧代哌啶-3-基-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异二氢吲哚-1,3-二酮治疗血液恶性肿瘤的方法 |
| WO2021080931A1 (en) * | 2019-10-21 | 2021-04-29 | Celgene Corporation | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneand salts thereof, and compositions comprising the same and their use |
| EP4095132A1 (en) * | 2020-01-20 | 2022-11-30 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| TW202241872A (zh) * | 2021-01-05 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用 |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| IL307257A (en) | 2021-03-29 | 2023-11-01 | Juno Therapeutics Inc | A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma |
| KR20230173107A (ko) * | 2021-04-21 | 2023-12-26 | 셀진 코포레이션 | 조합 치료법을 사용하여 b-세포 림프종을 치료하는 방법 |
| WO2022226011A1 (en) | 2021-04-21 | 2022-10-27 | Celgene Corporation | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| AU2022300184A1 (en) | 2021-06-21 | 2023-11-16 | Celgene Corporation | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione |
| WO2023025136A1 (zh) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | 异吲哚啉酮化合物及其用途 |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
| CN117088864A (zh) * | 2022-05-13 | 2023-11-21 | 广州智药生物科技有限公司 | 一种苯并[d]异恶唑类化合物及其应用 |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| DE60331537D1 (de) | 2002-05-17 | 2010-04-15 | Celgene Corp | Kombinationen zur behandlung von multiplem myelom |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| CN100398534C (zh) | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | 合成酞胺哌啶酮及其衍生物的方法 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| EP1797068B1 (en) | 2004-09-03 | 2013-10-09 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| MX2007005570A (es) | 2004-11-12 | 2007-07-09 | Celgene Corp | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos. |
| WO2007005972A1 (en) | 2005-06-30 | 2007-01-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
| MX2008002765A (es) | 2005-08-31 | 2008-04-07 | Celgene Corp | Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos. |
| AU2006332680A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
| US20080064876A1 (en) | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| MX2009001989A (es) | 2006-08-30 | 2009-03-09 | Celgene Corp | Compuestos de isoindolina 5-substituidos. |
| JP5567339B2 (ja) | 2006-09-15 | 2014-08-06 | セルジーン コーポレイション | Ｎ−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法 |
| WO2008115516A2 (en) | 2007-03-20 | 2008-09-25 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| MX2010005009A (es) | 2007-11-08 | 2010-05-27 | Celgene Corp | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. |
| RU2527952C2 (ru) | 2008-10-29 | 2014-09-10 | Селджин Корпорейшн | Изоиндолиновые соединения для применения при лечении рака |
| RU2567753C2 (ru) | 2010-02-11 | 2015-11-10 | Селджин Корпорейшн | Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| SG186378A1 (en) | 2010-06-23 | 2013-01-30 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| WO2012112919A1 (en) | 2011-02-17 | 2012-08-23 | Rhode Island Hostpital | Stromal derived factor inhibition and cxcr4 blockade |
| US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
| WO2016040449A1 (en) | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| RU2695521C9 (ru) | 2014-10-30 | 2019-08-19 | Канпу Биофармасьютикалс, Лтд. | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| NZ742001A (en) * | 2015-09-29 | 2019-06-28 | Kangpu Biopharmaceuticals Ltd | Pharmaceutical composition and application thereof comprising a benzoheterocyclic compound |
| ES2839523T3 (es) | 2016-01-14 | 2021-07-05 | Kangpu Biopharmaceuticals Ltd | Derivado de quinazolinona, procedimiento de preparación del mismo, composición farmacéutica y aplicaciones |
| HUE061989T2 (hu) | 2016-03-16 | 2023-09-28 | Kura Oncology Inc | Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CA3025805A1 (en) | 2016-06-23 | 2017-12-28 | James Bradner | Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use |
| EP3474900A4 (en) | 2016-06-23 | 2020-03-11 | Dana-Farber Cancer Institute, Inc. | DEGRADATION OF PROTEIN 9 (BRD9) CONTAINING BROMANOMAIN BY CONJUGATING BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHOD FOR USE THEREOF |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| SI3660004T1 (sl) | 2016-10-11 | 2023-08-31 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| EP3532464A4 (en) | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER |
| US10689366B2 (en) | 2016-11-01 | 2020-06-23 | Cornell University | Compounds for MALT1 degredation |
| WO2018098280A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| AU2017366693B2 (en) | 2016-12-01 | 2021-04-01 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| CN110267659A (zh) | 2016-12-08 | 2019-09-20 | 西奈山伊坎医学院 | 用于治疗cdk4/6介导的癌症的组合物和方法 |
| CN107056772A (zh) | 2017-01-23 | 2017-08-18 | 中国药科大学 | 基于cereblon配体诱导BET降解的双功能分子及其制备和应用 |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| CN110612294B (zh) | 2017-01-31 | 2024-01-16 | 阿尔维纳斯运营股份有限公司 | 人小脑蛋白配体和包含其的双官能化合物 |
| JP6773915B2 (ja) | 2017-02-13 | 2020-10-21 | カング バイオファーマシューティカルズ リミテッド | 前立腺癌を治療する組み合わせ、薬物組成物および治療方法 |
| CN108929307A (zh) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 |
| BR112020000442A2 (pt) * | 2017-07-10 | 2020-07-21 | Celgene Corporation | compostos antiproliferativos e métodos de uso dos mesmos |
| EP3652329B1 (en) | 2017-07-12 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| CN107698575A (zh) | 2017-09-26 | 2018-02-16 | 中国药科大学 | cereblon配体介导的新型BET蛋白降解的双功能分子及其制备和应用 |
| US11819532B2 (en) | 2018-04-23 | 2023-11-21 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
| CN108715585A (zh) | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| CN108690020A (zh) | 2018-07-04 | 2018-10-23 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
| CN108794453A (zh) | 2018-07-05 | 2018-11-13 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
-
2019
- 2019-04-22 CA CA3096404A patent/CA3096404A1/en active Pending
- 2019-04-22 ES ES19726225T patent/ES2959622T3/es active Active
- 2019-04-22 PL PL19726225.6T patent/PL3784663T3/pl unknown
- 2019-04-22 AU AU2019261273A patent/AU2019261273B2/en active Active
- 2019-04-22 RS RS20230890A patent/RS64663B1/sr unknown
- 2019-04-22 SG SG11202009237XA patent/SG11202009237XA/en unknown
- 2019-04-22 TW TW108113978A patent/TWI814815B/zh active
- 2019-04-22 US US16/390,815 patent/US11358952B2/en active Active
- 2019-04-22 PT PT197262256T patent/PT3784663T/pt unknown
- 2019-04-22 LT LTEPPCT/US2019/028471T patent/LT3784663T/lt unknown
- 2019-04-22 IL IL277435A patent/IL277435B1/en unknown
- 2019-04-22 FI FIEP19726225.6T patent/FI3784663T3/fi active
- 2019-04-22 AR ARP190101050A patent/AR114803A1/es unknown
- 2019-04-22 MX MX2020011183A patent/MX2020011183A/es unknown
- 2019-04-22 HR HRP20231199TT patent/HRP20231199T1/hr unknown
- 2019-04-22 SI SI201930632T patent/SI3784663T1/sl unknown
- 2019-04-22 KR KR1020207029644A patent/KR20210003103A/ko not_active Application Discontinuation
- 2019-04-22 BR BR112020021552-0A patent/BR112020021552B1/pt active IP Right Grant
- 2019-04-22 EA EA202092248A patent/EA202092248A1/ru unknown
- 2019-04-22 CN CN202110419043.3A patent/CN113214220B/zh active Active
- 2019-04-22 CN CN201980026036.8A patent/CN111989322B/zh active Active
- 2019-04-22 WO PCT/US2019/028471 patent/WO2019209692A1/en active Application Filing
- 2019-04-22 EP EP19726225.6A patent/EP3784663B1/en active Active
- 2019-04-22 PE PE2020001622A patent/PE20211375A1/es unknown
- 2019-04-22 HU HUE19726225A patent/HUE064340T2/hu unknown
- 2019-04-22 EP EP23184388.9A patent/EP4272737A3/en active Pending
- 2019-04-22 DK DK19726225.6T patent/DK3784663T3/da active
- 2019-04-22 JP JP2020558958A patent/JP7458324B2/ja active Active
-
2020
- 2020-10-15 CO CONC2020/0012824A patent/CO2020012824A2/es unknown
- 2020-10-16 CL CL2020002696A patent/CL2020002696A1/es unknown
- 2020-10-22 MX MX2023005160A patent/MX2023005160A/es unknown
-
2022
- 2022-05-12 US US17/743,313 patent/US11945804B2/en active Active
-
2023
- 2023-06-05 AU AU2023203504A patent/AU2023203504A1/en active Pending
-
2024
- 2024-03-18 JP JP2024041949A patent/JP2024073590A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019209692A5 (es) | ||
| HRP20231199T1 (hr) | Supstituirani spojevi 4-aminoizoindolin-1,3-diona i njihova upotreba za liječenje limfoma | |
| AU2020368542B2 (en) | Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety | |
| AU2021202962C1 (en) | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | |
| AU2017382436B2 (en) | Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides | |
| KR102642203B1 (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| RU2213089C2 (ru) | Моноциклические бензамиды производных 3- или 4-замещенного 4-(аминометил)пиперидина, способы их получения, фармацевтическая композиция, способ ее приготовления, производное карбоновой кислоты | |
| BR112020001825A2 (pt) | compostos e métodos para a degradação direcionada de receptor de androgênio | |
| BR112019015312A2 (pt) | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados | |
| ES2580961T3 (es) | Derivados Tiazolilfenil-bencenosulfonamido como Inhibidores de Cinasa | |
| JP2020518660A (ja) | Ｒａｆ分解性結合体化合物 | |
| ES2672992T3 (es) | Compuesto aromático | |
| JP2007524696A5 (es) | ||
| WO2014033631A1 (en) | N-(3-pyridyl) biarylamides as kinase inhibitors | |
| CA3199074A1 (en) | Compounds and methods for the targeted degradation of androgen receptor protein | |
| WO2013175388A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| CA2709786A1 (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | |
| TW201726647A (zh) | 醫藥化合物 | |
| JP2005525341A5 (es) | ||
| TW202214598A (zh) | 快速加速纖維肉瘤蛋白質降解之化合物及相關使用方法 | |
| EP4076650A1 (en) | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| EP0991644B1 (en) | Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors | |
| JP2008524269A5 (es) | ||
| WO2015135091A1 (en) | Piperazine derivatives as hiv protease inhibitors | |
| TWI818651B (zh) | 嘧啶化合物及其用途 |